View Older Stories View More Recent Stories

Nov 12, 2021 08:33AM New Real-World Data Show High Rate of Patient Adherence to TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
Nov 12, 2021 07:30AM Horizon Therapeutics (HZNP) Receives CHMP Positive Opinion for UPLIZNA as Monotherapy for Treatment of Adult Patients with Neuromyelitis Optica Spectrum Disorder
Nov 12, 2021 07:29AM Horizon Therapeutics plc Receives CHMP Positive Opinion for UPLIZNA® (inebilizumab) as a Monotherapy for the Treatment of Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Nov 9, 2021 08:00AM Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Nov 8, 2021 04:05PM Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
Nov 5, 2021 09:01AM Horizon Therapeutics plc Receives Top Workplace Awards in Chicago and San Francisco
Nov 4, 2021 01:00PM Results from PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) in Kidney Transplant Recipients with Uncontrolled Gout Presented as Part of American Society of Nephrology (ASN) Kidney Week
Nov 3, 2021 07:02AM Horizon Therapeutics plc Announces Chief Financial Officer Succession Plan
Nov 3, 2021 07:00AM Horizon Therapeutics plc Reports Record Third-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance
Nov 1, 2021 10:00AM New Data Being Presented at American College of Rheumatology Convergence 2021 Highlight Horizon’s Commitment to Improving Outcomes for People Living with Uncontrolled Gout
Oct 25, 2021 08:04AM Horizon Therapeutics (HZNP) Announces MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA with Methotrexate
Oct 25, 2021 08:00AM MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA® (pegloticase injection) with Methotrexate
Oct 22, 2021 09:29AM Horizon Therapeutics plc Named to Newsweek’s List of the Most Loved Workplaces for 2021
Oct 21, 2021 12:02PM Horizon Therapeutics (HZNP) Announces Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease
Oct 21, 2021 12:00PM Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
Oct 13, 2021 08:00AM New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
Oct 12, 2021 09:00AM New TEPEZZA® (teprotumumab-trbw) Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting
Oct 11, 2021 08:00AM Horizon Therapeutics plc to Release Third-Quarter 2021 Financial Results and Host Webcast on Nov. 3, 2021
Oct 6, 2021 08:00AM Horizon Therapeutics plc Named One of the 2021 Top 100 Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
Oct 4, 2021 08:34AM Horizon Therapeutics (HZNP) Announces New Analysis Published in Multiple Sclerosis Journal Assesses Long-Term Use of UPLIZNA for Treatment of NMOSD
Oct 4, 2021 08:30AM New Analysis Published in Multiple Sclerosis Journal Assesses Long-Term Use of UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Oct 4, 2021 08:08AM Horizon Therapeutics (HZNP) Announces New UPLIZNA Data in Neuromyelitis Optica Spectrum Disorder (NMOSD)
Oct 4, 2021 08:00AM Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2021
Sep 29, 2021 07:00AM Horizon Therapeutics plc Announces New Development Programs at Virtual R&D Day
Sep 23, 2021 09:00AM  Horizon Therapeutics plc Announces Agenda for Virtual R&D Day for Investors and Analysts on Sept. 29, 2021
Sep 23, 2021 08:30AM Horizon Therapeutics (HZNP) New Data Shows UPLIZNA Produces Rapid and Sustained B-Cell Depletion in African Americans with Neuromyelitis Optica Spectrum Disorder
Sep 23, 2021 08:30AM Horizon Therapeutics plc Announces Data Showing UPLIZNA® (inebilizumab-cdon) Also Produces Rapid and Sustained B-Cell Depletion in African Americans with Neuromyelitis Optica Spectrum Disorder (NMOSD
Sep 21, 2021 08:00AM Horizon Therapeutics plc Announces New Genetic Counselor Curated Algorithms and Next-Generation Sequencing Data as Winning Solutions of First-Ever Horizon Prize, Powered by MIT Solve, to Accelerate Ra
Sep 16, 2021 09:00AM Horizon Therapeutics plc Named One of the 2021 Best Workplaces for Women™ by Fortune and Great Place to Work®
Sep 7, 2021 08:32AM Horizon Therapeutics (HZNP) Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Chronic (Inactive) Thyroid Eye Disease
Sep 7, 2021 08:30AM  Horizon Therapeutics plc Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Chronic (Inactive) Thyroid Eye Disease (TED)
Sep 1, 2021 09:10AM Horizon Therapeutics plc Named One of PEOPLE’s 100 Companies That Care®
Aug 23, 2021 04:01PM Horizon Therapeutics plc to Participate in Upcoming Conferences
Aug 4, 2021 07:00AM Horizon Therapeutics plc Reports Record Second-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance
Jul 16, 2021 08:30AM Fortune Names Horizon Therapeutics One of the 2021 Best Workplaces for Millennials™
Jul 8, 2021 08:00AM Horizon Therapeutics plc to Release Second-Quarter 2021 Financial Results and Host Webcast on Aug. 4, 2021
Jun 30, 2021 08:00AM Horizon Therapeutics plc to Host Virtual R&D Day on Sept. 29, 2021
Jun 29, 2021 08:02AM Horizon Therapeutics (HZNP) Enrolls First Patient in Phase 2 Trial of HZN-7734 for the Treatment of Systemic Lupus Erythematosus
Jun 29, 2021 08:00AM Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating HZN-7734 for the Treatment of Systemic Lupus Erythematosus
Jun 28, 2021 09:00AM Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Community to FOCUS on Thyroid Eye Disease
Jun 21, 2021 07:32AM Arrowhead Pharmaceuticals (ARWR), Horizon Therapeutics (HZNP) Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Jun 21, 2021 07:30AM Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Jun 21, 2021 07:30AM Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Jun 18, 2021 12:32PM Horizon Therapeutics (HZNP) Announces Multiple Presentations on NMOSD at EAN
Jun 18, 2021 12:30PM Horizon Therapeutics plc Announces Multiple Presentations on Neuromyelitis Optica Spectrum Disorder (NMOSD) at the 7th Congress of the European Academy of Neurology (EAN)
Jun 17, 2021 07:06AM Horizon Therapeutics (HZNP) Announces Purchase of Manufacturing Facility to Support Growth of On-Market Rare Disease and Pipeline Biologics
Jun 17, 2021 07:00AM Horizon Therapeutics plc Announces Purchase of Manufacturing Facility to Support Growth of On-Market Rare Disease and Pipeline Biologics
Jun 2, 2021 08:00AM Horizon Therapeutics plc Presents New Data on Robust Pipeline at EULAR European Congress of Rheumatology
May 27, 2021 08:00AM Horizon Therapeutics plc Initiates ADVANCE Trial Evaluating KRYSTEXXA® (pegloticase injection) with Methotrexate for People Who Previously Developed Anti-Drug Antibodies on KRYSTEXXA Monotherapy
May 24, 2021 08:00AM Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
View More Recent Stories View Older Stories